Search results for "Neumonia"
showing 10 items of 657 documents
Chloroquine for COVID-19: rationale, facts, hopes
2020
The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
Chest CT in COVID-19 Pneumonia: Potentials and Limitations of Radiomics and Artificial Intelligence
2021
SARS-CoV-2 epidemics has resulted in an unprecedented global health crisis causing a high number of deaths with pneumonia being the most common manifestation. Chest CT is the best imaging modality to identify pulmonary involvement, but unfortunately there are no pathognomonic features for COVID-19 pneumonia, since many other infectious and non-infectious diseases may cause similar alterations. The adoption of artificial intelligence in biomedical imaging has the potential to revolutionize the identification, management, and the patient’s outcome. If adequately validated, it could be used as a support with predictive and prognostic purposes in symptomatic patients but also as a screening tes…
Why is COVID-19 especially impacting the African American population?
2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, penetrates human cells through direct binding with ...
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
2020
Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…
Contingency plan for the intensive care services for the COVID-19 pandemic
2020
Resumen En enero de 2020 China identifico un nuevo virus de la familia de los Coronaviridae como causante de varios casos de neumonia de origen desconocido. Inicialmente confinado a la ciudad de Wuhan, se extendio posteriormente fuera de las fronteras chinas. En Espana, el primer caso se declaro el 31 de enero de 2020. El 11 de marzo, la Organizacion Mundial de la Salud declaro el brote de coronavirus como pandemia. El 16 de marzo habia 139 paises afectados. Ante esta situacion, las Sociedades Cientificas SEMICYUC y SEEIUC han decidido la elaboracion de este plan de contingencia para dar respuesta a las necesidades que conllevara esta nueva enfermedad. Se pretende estimar la magnitud del pr…
There is a relationship between obesity and COVID‐19 but more information is needed
2020
Abstract We read with particular interest your comments in Obesity regarding the Coronavirus‐19 (COVID‐19) epidemic (1) and a related manuscript by Simonnet et al. (2). Resolution of the specific relationship between obesity and COVID‐19, two existing public health epidemics, is critically needed to potentially prevent health systems worldwide from being overburdened. Few studies describing COVID‐19 with rates of obesity exist, and most are based on heterogeneous populations (Table 1) (2‐7). In cohort studies with COVID‐19 disease, obesity rates are generally reported as no higher than population‐based estimates; in contrast, subgroups of critically ill patients (e.g, intensive care unit (I…
Clinical pathways for urology patients during the COVID-19 pandemic
2020
The public health emergency caused by the Coronavirus Disease 2019 (COVID-19) pandemic has resulted in a significant reallocation of health resources with a consequent reorganization of the clinical activities also in several urological centers. A panel of Italian urologists has agreed on a set of recommendations on pathways of pre-, intra- and post-operative care for urological patients undergoing urgent procedures or non-deferrable oncological interventions during the COVID-19 pandemic. Simplification of the diagnostic and staging pathway has to be prioritized in order to reduce hospital visits and consequently the risk of contagion. In absence of strict uniform regulations that impose th…
Impact of Health Care−Associated Infection in Patients with Aneurysmal Subarachnoid Hemorrhage
2018
In the era of antibiotics, nosocomial infections are still uncontrollable and represent a problem with a problematic solution. The terms nosocomial and health care−associated infections are both used for disease, absent at the time of admission, acquired by patients under medical care in the hospital or other health care facilities. Recently, the term health care−associated infection (HAI) has been introduced for the type of infection caused by a prolonged hospital stay, and it accounts for a significant risk factor for severe health issues leading to death. HAIs can occur during health care delivery for other diseases and even after patient discharge. Invasive devices such as catheters and…
Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach.
2020
Abstract The SARS‐CoV‐2 outbreak causing the respiratory disease COVID‐19 has left many chemists in academia without an obvious option to contribute to fighting the pandemic. Some of our recent experiences indicate that there are ways to overcome this dilemma. A three‐pronged approach is proposed.
Rapid molecular dissection of viral and bacterial immunomes
2006
The development of preventive or therapeutic recombinant vaccines and the generation of serodiagnostic assays for infectious diseases depend essentially on the availability of molecularly defined antigens. A major bottleneck for the identification of suitable target antigens for many pathogens is the isolation of sufficient amounts of material for subsequent genomic or proteomic screening. Applying a highly efficient expression cloning strategy to the human pathogens vaccinia virus (VV) and Chlamydia pneumoniae (CP), we demonstrate that sub-nanogram amounts of isolated nucleic acids can be utilized to determine comprehensive sets of immunodominant antigens. Remarkably, the approach not only…